WE STRONGLY URGE ALL CONSUMERS TO READ THIS BEFORE CLICKING ON ANY OF THE ADVERTISEMENTS FOUND ON THE ACOMPLIA REPORT WEBSITE.

The Zimulti Acomplia Report -- offered free on the web as a news resource about the diet drug Acomplia / Zimulti (rimonabant) and other weight-loss drugs under development -- relies on advertising revenue for support.

Medical Week News, Inc., publisher of the Zimulti Acomplia Report, is a media company. We do NOT sell any type of pharmaceutical product, dietary aid or weight-loss program.

Many advertisements on this site are placed and controlled by outside advertising networks, such as Google. The Zimulti Acomplia Report does NOT select or control the advertisements placed on this site by the outside networks, and does NOT evaluate or endorse any of the advertisers, or their advertised products and services.

In addition to the ads placed by advertising networks, the Zimulti Acomplia Report sells advertisements directly to shops -- both based in the U.S. and other countries -- that sell prescription and non-prescription drugs over the Internet. These companies may sell drugs to consumers worldwide, or they may sell only to consumers in certain countries. None of these companies, their websites, or their sales policies is under our control, and we offer no endorsement or warranties of any kind.

UNLESS EXPRESSLY STATED BY US, WE DO NOT RECOMMEND OR ENDORSE THE PRODUCTS, SERVICES OR WEB SITES OF ANY ADVERTISER, OR MAKE ANY DETERMINATION WHETHER ANY PRODUCT OR SERVICE THEY ARE SELLING MAY BE NECESSARY, APPROPRIATE OR SAFE FOR YOU. BUYER BEWARE.

We do not knowingly accept advertising from illegitimate pharmacies, and we will cancel any advertising upon being requested to do so by the U.S. Food and Drug Administration or an appropriate governmental agency.

However, it is important you understand that the fact that an ad appears on this website does NOT in any way imply that the advertiser, the product or the service has been screened by and/or approved by Zimulti Acomplia Report, Medical Week News, Inc, the FDA, or any other governmental agency.

We also suggest that you visit the FDA’s “Buying Rx Drugs Online” web portal at http://www.fda.gov/oc/buyonline/default.htm, which contains information for consumers, including tips and warnings on how to spot health fraud, frequently asked questions (FAQ’s) and where to report suspected “rogue” sites.

We would also encourage you to read excerpts reprinted below of Congressional testimony by William K. Hubbard, associate FDA commissioner for policy and planning, on the sale of drugs over the internet:

"FDA remains concerned about consumers directly purchasing foreign unapproved drugs through the Internet, because of the Agency’s continued concerns that there is not sufficient information or means to assure that these products are as safe and effective as products sold within the United States.

"As beneficial as this technology can be, the Internet also has created a marketplace for the sale of unapproved drugs, prescription drugs dispensed without a valid prescription, or products marketed with fraudulent health claims. Consumers may have difficulty identifying which sites sell legitimate products. As FDA considers the issues related to online drug sales, we recognize that there are various types of websites engaged in drug sales. Many sites focus on selling prescription drugs and are referred to by some as “Internet pharmacies.” These sites offer for sale either FDA-approved prescription drug products, or in some cases, unapproved, illegal versions of prescription drugs.

"Patients who buy prescription drugs from an illegitimate site are at risk of suffering adverse events, some of which can be life threatening. These risks include potential side effects from inappropriately prescribed medications, dangerous drug interactions or drug contamination. Patients are also at risk because they often don’t know what they are getting when they purchase some of these drugs. Although some patients may purchase genuine product, others may unknowingly buy counterfeit copies that contain inert ingredients, legitimate drugs that are outdated and have been diverted to illegitimate resellers, or dangerous sub-potent or super-potent products that were improperly manufactured.

"FDA is concerned about the proliferation of sites that substitute a simple online questionnaire for a face-to-face examination and patient supervision by a health care practitioner. According to the American Medical Association, a health care practitioner who offers a prescription for a patient he or she has never seen before, based solely on an online questionnaire, generally does not meet the appropriate medical standard of care.

"FDA is concerned that the selection of prescription drug products or treatment regimens for a particular patient should be made with the advice of a licensed health care practitioner who is familiar with the patient’s current health status and past medical history. In situations where a customary physician-patient relationship does not exist, the patient may be practicing what amounts to self-diagnosis. Consequently, the risk of negative outcomes such as harmful drug interactions, contraindications, allergic reactions or improper dosing is potentially magnified.

"The sale of drugs to U.S. residents via foreign websites is an extremely challenging area. Medications sold on the Internet that may be legal in foreign countries may not be approved for use in the U.S. Products not approved for sale in the U.S. often do not conform to the cGMP and quality assurance requirements in U.S. laws and regulations, and it is illegal for a foreign pharmacy to ship such drugs into the U.S."